{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:36Z","timestamp":1791924756224,"version":"4.3.4"},"reference-count":24,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,7,22]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>With the recent development of novel, more potent cancer treatment, in particular, immune \u2018checkpoint inhibitors\u2019, cases of neurological immune-related adverse events are on the rise. Although rare, this includes Guillain-Barr\u00e9 Syndrome (GBS). We present the case of a 68-year-old male who was admitted with sudden onset of worsening neurological symptoms following immunotherapy treatment. These symptoms progressed quickly to respiratory failure requiring intubation and admission to the intensive care unit. He was thoroughly investigated and is believed to have an axonal neuropathy in the form of Miller Fisher Syndrome (MFS) variant of GBS, secondary to immunotherapy treatment. He was initially treated with intravenous immunoglobulin, and later, perhaps more effectively, with high dose steroids which significantly improved his symptoms. This case of checkpoint inhibitor-induced MFS is one of few in the literature and is an important reminder of the potential for new immunotherapeutic agents to cause significant neurotoxic effects. These should be promptly and thoroughly investigated, in particular, as the management of these patients can differ from standard treatments used in these conditions.<\/jats:p>","DOI":"10.1136\/bcr-2019-229443","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T07:15:22Z","timestamp":1565766922000},"page":"e229443","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["A rare case of Miller Fisher variant of Guillain-Barr<b>\u00e9<\/b> Syndrome (GBS) induced by a checkpoint inhibitor"],"prefix":"10.1136","volume":"12","author":[{"given":"Caitlin Jane","family":"McNeill","sequence":"first","affiliation":[{"name":"Respiratory, Musgrove Park Hospital, Taunton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janev","family":"Fehmi","sequence":"additional","affiliation":[{"name":"Neurology, Southmead Hospital, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gladwin","sequence":"additional","affiliation":[{"name":"Intensive Care, Royal Free Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Price","sequence":"additional","affiliation":[{"name":"Neurology, Musgrove Park Hospital, Taunton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"2025082712462355000_12.8.e229443.1","unstructured":"Nivolumab. Accessdata.fda.gov. 2018. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125554s012lbl.pdf\u00a0[cited 6 Jul 2018]."},{"key":"2025082712462355000_12.8.e229443.2","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014567470"},{"key":"2025082712462355000_12.8.e229443.3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237"},{"key":"2025082712462355000_12.8.e229443.4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"2025082712462355000_12.8.e229443.5","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Ctep.cancer.gov. 2018. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50\u00a0[cited 6 Jul 2018]."},{"key":"2025082712462355000_12.8.e229443.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025082712462355000_12.8.e229443.7","doi-asserted-by":"crossref","unstructured":"Juster-Switlyk K , Johnson N . Neurologic Immune-related Adverse Events Associated with Check-point Inhibitors: A Case Study and Systematic Review of the Literature. Neurology 2018;90.","DOI":"10.1212\/WNL.90.15_supplement.P4.161"},{"key":"2025082712462355000_12.8.e229443.8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/1941874418778957","article-title":"Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma","volume":"8","author":"Baird-Gunning","year":"2018","journal-title":"Neurohospitalist"},{"key":"2025082712462355000_12.8.e229443.9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"2025082712462355000_12.8.e229443.10","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s10072-018-3465-4","article-title":"Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer","volume":"39","author":"Naito","year":"2018","journal-title":"Neurol Sci"},{"key":"2025082712462355000_12.8.e229443.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"2025082712462355000_12.8.e229443.12","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2012-000447"},{"key":"2025082712462355000_12.8.e229443.13","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou001"},{"key":"2025082712462355000_12.8.e229443.14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/NRL.0000000000000176","article-title":"The Mayo Clinic experience with the neurological complications of the CTLA-4 inhibitor Ipilimumab","volume":"23","author":"Ruff","year":"2018","journal-title":"Neurologist"},{"key":"2025082712462355000_12.8.e229443.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0217"},{"key":"2025082712462355000_12.8.e229443.16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-2548","article-title":"PD-1 antibody-induced Guillain-Barr\u00e9 syndrome in a patient with metastatic melanoma","volume":"97","author":"Schneiderbauer","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2025082712462355000_12.8.e229443.17","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31827807dd"},{"key":"2025082712462355000_12.8.e229443.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr028"},{"key":"2025082712462355000_12.8.e229443.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1683"},{"key":"2025082712462355000_12.8.e229443.20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine"},{"key":"2025082712462355000_12.8.e229443.21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fneur.2018.00150","article-title":"Myasthenia gravis induced by Ipilimumab in a patient with metastatic melanoma","volume":"9","author":"Montes","year":"2018","journal-title":"Front Neurol"},{"key":"2025082712462355000_12.8.e229443.22","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10072-018-3471-6","article-title":"Ipilimumab treatment associated with myasthenic crises and unfavorable disease course","volume":"39","author":"Derle","year":"2018","journal-title":"Neurol Sci"},{"key":"2025082712462355000_12.8.e229443.23","unstructured":"Miller Fisher Syndrome Information Page. National Institute of Neurological Disorders and Stroke. Available:\u00a0 https:\/\/www.ninds.nih.gov\/Disorders\/All-Disorders\/Miller-Fisher-Syndrome-Information-Page [Accessed Dec 18]."},{"key":"2025082712462355000_12.8.e229443.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2003.11.017"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-229443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:46:28Z","timestamp":1756323988000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-229443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,13]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bcr-2019-229443"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-229443","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}